A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

被引：0
|
作者：
Berenson, James R. [1 ]
Yellin, Ori
Cartmell, Alan D. [2 ]
Woliver, Thomas B. S. [3 ]
Flam, Marshall S. [4 ]
Nassir, Youram [5 ]
Vescio, Robert [6 ]
Swift, Regina A. [7 ]
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA USA
[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[3] Canc Ctr Santa Barbara, Santa Barbara, CA USA
[4] St Agnes Canc Ctr, Hem Onc Med Grp Fresno, Fresno, CA USA
[5] Canc Care Inst, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Vames R Berenson MD Inc, W Hollywood, CA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1254 / 1255
页数：2
相关论文
共 50 条
  • [1] A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone (DVD) for relapsed or refractory (R/R) multiple myeloma (MM)
    Waterman, G. N.
    Yellin, O.
    Swift, R. A.
    Hilger, J.
    Berenson, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy L.
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    [J]. BLOOD, 2011, 118 (21) : 1705 - 1706
  • [3] A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM)
    Hilger, James D.
    Berenson, James R.
    Klein, Leonard M.
    Bessudo, Alberto
    Rosen, Peter J.
    Eshaghian, Shahrooz
    Chamras, Hilda
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma
    Lazaryan, Aleksandr
    Baz, Rachid
    Hussein, Mohamad A., Jr.
    Elson, Paul
    Faiman, Beth
    Habecker, Becky
    Karam, Mary Ann
    Reed, Janice
    Hamilton, Kimberly
    Bruening, Kellie
    Srkalovic, Gordan
    Andresen, Steven
    Kalaycio, Matt
    Sweetenham, John William
    Sobecks, Ronald
    Dean, Robert
    Knight, Robert
    Zeldis, Jerome B.
    Reu, Frederic J.
    [J]. BLOOD, 2010, 116 (21) : 821 - 822
  • [5] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    Berenson, J. R.
    Yellin, O.
    Kazamel, T.
    Hilger, J. D.
    Chen, C-S
    Cartmell, A.
    Woliver, T.
    Flam, M.
    Bravin, E.
    Nassir, Y.
    Vescio, R.
    Swift, R. A.
    [J]. LEUKEMIA, 2012, 26 (07) : 1675 - 1680
  • [6] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    J R Berenson
    O Yellin
    T Kazamel
    J D Hilger
    C-S Chen
    A Cartmell
    T Woliver
    M Flam
    E Bravin
    Y Nassir
    R Vescio
    R A Swift
    [J]. Leukemia, 2012, 26 : 1675 - 1680
  • [7] A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib and dexamethasone regime for patients with previously untreated multiple myeloma (MM)
    Berenson, J. R.
    Yellin, O.
    Chen, C.
    Patel, R.
    Bessudo, A.
    Boccia, R. V.
    Yang, H.
    Gupta, V.
    Hilger, J.
    Swift, R. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark A.
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille N.
    DiPersio, John F.
    Tomasson, Michael H.
    Wildes, Tanya M.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    [J]. BLOOD, 2016, 128 (22)
  • [9] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [10] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille
    DiPersio, John
    Tomasson, Michael
    Wildes, Tanya
    Stockerl-Goldstein, Keith
    Vij, Ravi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E56 - E56
12345